There is no way to know what kind of Market Cap we'd have if RVX was trading on the Nasdaq....its conceivable to me that the company could have attracted the attention of even bigger bearish players, and instead of short interest being less than 1%, it could have been 5 or 10% and maybe even higher.  The Naz might be something of a panacea to some, (a cure all) but there's no way to know for sure....its a moot (completely debatable) point.   

Another of Eastern's biotech bets had to effect a reverse split, Peregrine Pharma, in order to maintain its Naz listing.  And Peregrine had revenue from its Contract Drug Manufacturing subsiduary.